Steele K, Greenstone M, Lasserson J A
Thoracic Department, Royal Bournemouth Hospital, Castle Lane East, Bournemouth, UK, BH7 7DW.
Cochrane Database Syst Rev. 2001;2000(1):CD002734. doi: 10.1002/14651858.CD002734.
Bronchiectasis is characterised by chronic sputum production,bronchial wall dilation,recurrent infection and airflow limitation. Methylxanthines are used in the management of airflow limitation associated with asthma and COPD, where they are also purported to have anti-inflammatory properties. In theory they may be of use in bronchiectasis.
To determine the efficacy of methylxanthines in the treatment of bronchiectasis.
The Cochrane Airways Group clinical trials register derived from MEDLINE,EMBASE and hand searches using the terms bronchiectasis, aminophylline, theophylline and methyl- xanthine
Only randomised controlled trials were to be considered.
The results of the searches were reviewed by two authors. Searches yielded seven trials none of which met the inclusion criteria.
No randomised controlled trials were identified.
REVIEWER'S CONCLUSIONS: Further research is required to establish if the methylxanthines have a role in the treatment of bronchiectasis.
支气管扩张症的特征为长期咳痰、支气管壁扩张、反复感染和气流受限。甲基黄嘌呤类药物用于治疗与哮喘和慢性阻塞性肺疾病（COPD）相关的气流受限，据称它们还具有抗炎特性。理论上，它们可能对支气管扩张症有用。
确定甲基黄嘌呤类药物治疗支气管扩张症的疗效。
Cochrane气道组临床试验注册库来源于MEDLINE、EMBASE，并通过手工检索，检索词为支气管扩张症、氨茶碱、茶碱和甲基黄嘌呤。
仅考虑随机对照试验。
两名作者对检索结果进行了审查。检索结果有7项试验，但均不符合纳入标准。
未发现随机对照试验。
需要进一步研究以确定甲基黄嘌呤类药物是否对支气管扩张症的治疗有作用。
